It is a “switch-control” inhibitor, that stabilizes an inactive conformation of CSF1R, thereby blocking CSF1-driven recruitment and survival signals for tumor-associated macrophages, and the CSF1-overexpressing neoplastic cells that characterize TGCT (Smith et al., 2021[112]). This evidence concerns the gene CSF1R and neoplasm.